A Trial of SHR6508 in Secondary Hyperparathyroidism

Condition:   Secondary Hyperparathyroidism Intervention:   Drug: SHR6508；Placebo Sponsor:   Shanghai Hengrui Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials